https://www.selleckchem.com/pr....oducts/tabersonine.h
63; 95% CI, 0.51-3.51; = 0.214 and the use of statin; adjusted HR, 1.86; 95% CI, 0.76-4.58; = 0.177). Mild to moderate AS does not have a benign course. The presence of CAD and statin use may affect the long-term prognosis of patients with mild to moderate AS. Mild to moderate AS does not have a benign course. The presence of CAD and statin use may affect the long-term prognosis of patients with mild to moderate AS. The development process of clinical practice guidelines (CPGs) must adhere to development standards and must be suppor
Like
Comment
Share
